Replies to post #221357 on Cytodyn Inc (CYDY)

[misiu143]

That is the ONLY problem with leronlimab , If leronlimab was Gilead, trending with results drug ,
drug with severe side effects , we will be long approved.

Like a Biogen drug for Alz they approved last year.
--Drug showing no clinical significance
--Met no endpoints,
--No p-value
-- About 30 % developing severe side effects including stroke..

All imo.

GLTA longs.